Shanghai Wennai Pharmaceutical Technology Co. Ltd. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of acute and chronic pain.

Biocells (Beijing) Biotech Co. Ltd. has divulged aquaporin-4 (AQP4) inhibitors potentially useful for the treatment of cerebral ischemia.

Bial-Portela & Ca SA has identified orexin OX1 receptor antagonists reported to be useful for the treatment of cognitive, sleep, anxiety and eating disorders, depression, obesity, schizophrenia, substance abuse and dependence, among others.

2A Biosciences Inc. has synthesized tryptamine derivatives acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric, neurodegenerative, neurodevelopmental, inflammatory and eye disorders.

Bsense Bio Therapeutics Ltd. has disclosed new potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators and transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonists reported to be useful for the treatment of neuropathic pain, pruritus and tinnitus.

Brii Biosciences Inc. has identified substituted 2-(3,5-dichloro-4-(4-hydroxy-benzyl)phenoxy)acetamide derivatives that are prodrugs of thyroid hormone receptor β (TH-β) agonists and reported to be useful for the treatment of multiple sclerosis.

Researchers in from Nanjing Drum Tower Hospital have presented data from a study that investigated the role of immunoglobulin superfamily member 6 (IGSF6) microglia during ischemic stroke.